Trial Profile
A Three-part Open-label, Non-randomised, Dose-escalation Study to Investigate the Safety and Tolerability of GSK3039294 Administered as a Single Dose to Healthy Volunteers, and as Repeat Dose to Healthy Volunteers and Patients With Systemic Amyloidosis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 3039294 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 16 Jul 2018 Status changed from active, no longer recruiting to discontinued.
- 03 Apr 2018 Status changed from suspended to active, no longer recruiting.
- 22 Nov 2017 Planned End Date changed from 17 Oct 2017 to 19 Aug 2019.